The Use of Olanzapine Versus Metoclopramide for the Treatment of Breakthrough Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

被引：0
|
作者：
Navari, Rudolph [1 ,2 ]
Nagy, Cindy [1 ]
Gray, Sarah [2 ]
机构：
[1] Indiana Univ Sch Med, South Bend, IN USA
[2] Univ Notre Dame, Notre Dame, IN 46556 USA
来源：
PSYCHO-ONCOLOGY | 2013年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [31] Efficacy of NEPA for prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic chemotherapy and usefulness of adding olanzapine for prior grade 2 or higher emesis
    Na, J.
    Park, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1604 - S1604
  • [32] Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
    Hu, Zhihuang
    Liang, Wenhua
    Yang, Yunpeng
    Keefe, Dorothy
    Ma, Yuxiang
    Zhao, Yuanyuan
    Xue, Cong
    Huang, Yan
    Zhao, Hongyun
    Chen, Likun
    Chan, Alexandre
    Zhang, Li
    MEDICINE, 2016, 95 (02)
  • [33] Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China
    Sun, Yu
    Zheng, Yuzhu
    Yang, Xiaoyun
    Xie, Ke
    Du, Chi
    He, Lang
    Gui, Yan
    Fu, Jiangping
    Li, Changlin
    Zhang, Huiling
    Zhu, Li
    Bie, Jun
    Sun, Yi
    Fu, Yu
    Zhou, Yangang
    Shou, Feng
    Wang, Yan
    Zhu, Jiang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (09) : 2701 - 2708
  • [34] Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China
    Yu Sun
    Yuzhu Zheng
    Xiaoyun Yang
    Ke Xie
    Chi Du
    Lang He
    Yan Gui
    Jiangping Fu
    Changlin Li
    Huiling Zhang
    Li Zhu
    Jun Bie
    Yi Sun
    Yu Fu
    Yangang Zhou
    Feng Shou
    Yan Wang
    Jiang Zhu
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 2701 - 2708
  • [35] Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy
    Shih, Ya-Chen Tina
    Xu, Ying
    Elting, Linda S.
    CANCER, 2007, 110 (03) : 678 - 685
  • [36] ONDANSETRON VERSUS METOCLOPRAMIDE IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING - A METAANALYSIS
    RUSTHOVEN, J
    OBRIEN, BJ
    ROCCHI, A
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1992, 1 (04) : 443 - 450
  • [37] Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron
    Coluzzi, Flaminia
    Mattia, Consalvo
    FUTURE ONCOLOGY, 2016, 12 (16) : 1865 - 1876
  • [38] Safety of Palonosetron and Ondansetron in Preventing Chemotherapy-induced Nausea and Vomiting in Pediatric Patients Receiving Moderately-or Highly-Emetogenic Chemotherapy
    Kovacs, G.
    Wachtel, A. E.
    Basharova, E. V.
    Spinelli, T.
    Nicolas, P.
    Cipriani, S.
    Kabickova, E.
    DRUG SAFETY, 2014, 37 (10) : 843 - 843
  • [39] Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Zelek, Laurent
    Navari, Rudolph
    Aapro, Matti
    Scotte, Florian
    CANCER MEDICINE, 2023, 12 (15): : 15769 - 15776
  • [40] NAUSEA AND VOMITING PERSPECTIVES OF CHILDREN RECEIVING MODERATE TO HIGHLY EMETOGENIC CHEMOTHERAPY TREATMENT
    Rodgers, Cheryl
    Norville, Robbie
    Poon, Connie
    Hesselgrave, Joy
    Gregurich, Mary Ann
    PEDIATRIC BLOOD & CANCER, 2010, 55 (05) : 987 - 987
12345